Amneal Pharmaceuticals (AMRX) Reports Q3 2025 Earnings Results
Amneal Pharmaceuticals (AMRX) reported Q3 2025 earnings with total revenue of $785 million, a 12% increase year-over-year. Adjusted EBITDA rose 1% to $160 million, and earnings per share increased 6% to $0.17. The company highlighted growth across its segments, including a 24% increase in AvKARE revenue and strong performance in the Affordable Medicines segment.
Tickers: $AMRX
Topics: earnings financial performance revenue segment performance stock price